Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Applied Therapeutics Inc. (APLT : NSDQ)
 
 • Company Description   
Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company's product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment of diabetic retinopathy which are in clinical stage. Applied Therapeutics Inc. is based in New York, United States.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.52 Daily Weekly Monthly
20 Day Moving Average: 159,820 shares
Shares Outstanding: 26.24 (millions)
Market Capitalization: $39.88 (millions)
Beta: 1.52
52 Week High: $25.59
52 Week Low: $1.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.12% -15.66%
12 Week -22.05% -14.30%
Year To Date -83.02% -79.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
545 5TH AVENUE SUITE 1400
-
NEW YORK,NY 10017
USA
ph: 212-220-9226
fax: -
maeve@argotpartners.com http://www.appliedtherapeutics.com
 
 • General Corporate Information   
Officers
Shoshana Shendelman - Chair of the Board President and Chief Executive O
Chids Mahadevan - Senior Vice President of Finance
Steven Ortega - Chief Accounting Officer
Les Funtleyder - Director
Teena Lerner - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03828A101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 26.24
Most Recent Split Date: (:1)
Beta: 1.52
Market Capitalization: $39.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.46 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.95
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 12.00%
vs. Previous Quarter: 15.38%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -137.70
12/31/21 - -106.41
09/30/21 - -98.12
ROA
03/31/22 - -101.89
12/31/21 - -84.19
09/30/21 - -79.12
Current Ratio
03/31/22 - 2.86
12/31/21 - 3.34
09/30/21 - 3.79
Quick Ratio
03/31/22 - 2.86
12/31/21 - 3.34
09/30/21 - 3.79
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.60
12/31/21 - 2.39
09/30/21 - 3.31
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©